
Warm nights and ill premature babies?
A study from Hanover investigates the spread of Klebsiella in the neonatal intensive care unit.

TWINCORE was founded in 2008 by the Helmholtz Centre for Infection Research and the Hannover Medical School. We combine the expertise of medical professionals and scientists from a wide range of disciplines to find answers to the pressing questions in infection research. Our focus: translational research – the bridge between basic science and clinical application.
This year's TWINCORE Symposium
Pathways to infection resilience
will take place on 3 - 4 September.

A study from Hanover investigates the spread of Klebsiella in the neonatal intensive care unit.

TWINCORE researchers investigate gene activity in host cells

Diverse Origins – One Goal
We conduct translational infection research to improve the prevention, diagnosis and treatment of infectious diseases in humans. We focus on three areas that characterize our research work. Find out here how we proceed and what results we achieve.
Under the leadership of our best scientists, various labs are working on different projects within our research topics.
Szafrański S, Joshi A, Steglich M, Yang I, Qu T, Behrens W, Muthukumarasamy U, Melidis D, Schaefer-Dreyer P, Grischke J, Hegermann J, Nejdl W, Häussler S, Stiesch M
Stankov M, Bruhn M, Hoffmann M, Salam A, Eichmann A, Nehlmeier I, Manthey L, Witte T, Pöhlmann S, Ahrenstorf G, Happle C, Dopfer-Jablonka A, Kalinke U, Behrens G
Sidarous L, Ibrahim M, Elhadidy M, Abouelfetouh A, Saif N, Aboelnaga N, Shehat M, Youssef M, Badr E
Immunomodulatory drugs can have systemic side effects. This project is testing nanocarriers that deliver drugs specifically into myeloid immune cells in order to reduce side effects and increase the local effect.
The project investigates how HCMV is recognized by the immune system and which mechanisms the virus uses to camouflage itself. The aim is to understand the immune reactions and develop therapies for severely affected patients.
In this project, antibodies that help to ward off infections are being investigated in more detail. The aim is to find characteristics that have a protective effect against certain pathogens by comparing different antibody profiles in infections and vaccinations.
Older people are at high risk of a poor immune response to the flu vaccine. Together with partners, we are looking for biomarkers and risk factors for this inadequate response and are investigating ways to improve the vaccination response.
Ralf Meister, Bishop of the Evangelical-Lutheran Church of Hanover
“Participation and Resilience at the Interface between Science and Society”
Moritz Gaidt, IMP - Research Institute of Molecular Pathology, Vienna
Marylyn M. Addo - UKE Hamburg

